{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wierda WG"],"funding":["NCRR NIH HHS","FDA HHS","NCI NIH HHS"],"pagination":["1893-900"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4556366"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(11)"],"pubmed_abstract":["Ligation of CD40 on chronic lymphocytic leukemia (CLL) cells induces phenotypic and biochemical changes that facilitate CLL cell-T cell interactions and enhances the sensitivity of CLL cells to clearance by adaptive and innate immune-effector mechanisms. CLL cells can be transduced to express CD40 ligand (CD154) using a replication-defective adenovirus vector, thereby cross-linking CD40 on transduced and non-transduced, bystander CLL cells. In a previous study, patients received infusions of autologous CLL cells, transduced to express murine CD154 (mCD154), which induced anti-leukemic immune responses, but also anti-mCD154 antibodies. In this study, we report a phase I study, in which patients were infused with 1 × 10(8), 3 × 10(8) or 1 × 10(9) autologous CLL cells transduced ex vivo to ex"],"journal":["Leukemia"],"pubmed_title":["A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154."],"pmcid":["PMC4556366"],"funding_grant_id":["M01 RR000827","P01 CA081534","K08 CA106605","R01 FD003427"],"pubmed_authors":["Jalayer A","Kipps TJ","McMannis J","Wierda WG","Castro JE","Aguillon R","Sampath D","Prussak CE","Keating M"],"additional_accession":[]},"is_claimable":false,"name":"A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154.","description":"Ligation of CD40 on chronic lymphocytic leukemia (CLL) cells induces phenotypic and biochemical changes that facilitate CLL cell-T cell interactions and enhances the sensitivity of CLL cells to clearance by adaptive and innate immune-effector mechanisms. CLL cells can be transduced to express CD40 ligand (CD154) using a replication-defective adenovirus vector, thereby cross-linking CD40 on transduced and non-transduced, bystander CLL cells. In a previous study, patients received infusions of autologous CLL cells, transduced to express murine CD154 (mCD154), which induced anti-leukemic immune responses, but also anti-mCD154 antibodies. In this study, we report a phase I study, in which patients were infused with 1 × 10(8), 3 × 10(8) or 1 × 10(9) autologous CLL cells transduced ex vivo to ex","dates":{"release":"2010-01-01T00:00:00Z","publication":"2010 Nov","modification":"2025-04-19T14:58:32.9Z","creation":"2019-03-27T01:57:37Z"},"accession":"S-EPMC4556366","cross_references":{"pubmed":["20882050"],"doi":["10.1038/leu.2010.191"]}}